Plus Therapeutics announces presentation of new data on REYOBIQ

Plus Therapeutics (PSTV) announces the presentation of new data on its lead drug REYOBIQ during both an oral presentation and a poster presented at the Nuclear Medicine and Neurooncology Conference. The meeting was held May 9-10, 2025 in Vienna, Austria. Data demonstrated: Dose dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space reaching 253Gy in Cohort 5. Neuroimaging response data was available for 17 patients as of the data cutoff with five of those showing a partial response. An additional eight patients showed stable disease by neuroimaging through day 112 for a Clinical Benefit Rate of 76%. Additionally, 87% of subjects demonstrated clinical response based on the physician evaluation. No dose limiting toxicity observed in the first four cohorts, with a grade 4 DLT, one in each of Cohorts 5 and 6. RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. In addition, of the seven patients who received a response of better than 80% in reduction of LM tumor cells in the cerebrospinal fluid, five survived at least one year following initial treatment. The study reports that three of those five were retreated via compassionate use.